Meningioma
Jump to navigation
Jump to search
| Section editor | |
|---|---|
 |
Seema Nagpal, MD Stanford University Palo Alto, CA, USA |
Are you looking for a regimen but can't find it here? For placebo or observational studies in this condition, please visit this page. If you still can't find it, please let us know so we can add it!
0 regimens on this page
0 variants on this page
|
Guidelines
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only.
EANO
NCCN
- NCCN does not have guidelines at this granular level; please see NCCN Guidelines - Central Nervous System Cancers.
Unresectable, all lines of therapy
Placebo
Regimen
| Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Ji et al. 2015 (SWOG S9005) | 1992-1998 | Phase 3 (C) | Mifepristone | Did not meet primary endpoint of FFS |
No active antineoplastic treatment.
References
- SWOG S9005: Ji Y, Rankin C, Grunberg S, Sherrod AE, Ahmadi J, Townsend JJ, Feun LG, Fredericks RK, Russell CA, Kabbinavar FF, Stelzer KJ, Schott A, Verschraegen C. Double-blind phase III randomized trial of the antiprogestin agent mifepristone in the treatment of unresectable meningioma: SWOG S9005. J Clin Oncol. 2015 Dec 1;33(34):4093-8. Epub 2015 Nov 2. link to original article link to PMC article PubMed NCT03015701